Compare Fluence Energy Inc. Class A Common Stock (FLNC) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance

Fluence Energy Inc. Class A Common StockTrade

Oruka Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Fluence Energy Inc. Class A Common Stock vs Oruka Therapeutics Inc. Common Stock — how do they compare? Fluence Energy Inc. Class A Common Stock trades at $6.18 (market cap $969.93M), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 5.3× Fluence Energy Inc. Class A Common Stock's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Fluence Energy Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fluence Energy Inc. Class A Common Stock for 0 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.

	FLNC	ORKA
Market Cap	$969.93M	$5.18B
Volume	7,001,648	490,798
Sector	Utilities	Health
52-Week High	$32.23	$113.08
52-Week Low	$6.21	$26.19
Typical Hold Time	0 Days	0 Days
Enterprise Value	$1.02B	$4.31B

View details →View details →

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FLNC

100% Buy0% Sell

Avg holding period · 0 Days

ORKA

100% Buy0% Sell

Avg holding period · 0 Days

Top news

Latest headlines on both assets

FLNC

Vattenfall commissions Fluence for 1 GWh battery storage in Brunsbüttel, Germany, operational by 2028.Globe Newswire · 22 hours agoBullish Vattenfall awards Fluence a 1 GWh battery storage project in Germany, set to operate by 2028.GlobeNewsWire · 1 day agoBullish View details →

ORKA

View details →

About Fluence Energy Inc. Class A Common Stock

Fluence Energy Inc. designs and delivers energy storage products, operational services, and asset optimization software for renewable-energy and storage applications worldwide.

About Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.